Alnylam Pharmaceuticals

Alnylam is translating RNA interference (RNAi) into an entirely new class of innovative drugs, which has the potential to transform the lives of patients with limited or inadequate treatment options. The company has already established corresponding product pipelines in genetic diseases, cardiometabolic diseases, liver infectious diseases, central nervous system diseases, and ophthalmic diseases.